Allarity Therapeutics Statistics
Share Statistics
Allarity Therapeutics has 4.43M shares outstanding. The number of shares has increased by -76% in one year.
| Shares Outstanding | 4.43M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -94.48% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 3.96M |
| Failed to Deliver (FTD) Shares | 8.79K |
| FTD / Avg. Volume | 1.45% |
Short Selling Information
The latest short interest is 179.44K, so 4.05% of the outstanding shares have been sold short.
| Short Interest | 179.44K |
| Short % of Shares Out | 4.05% |
| Short % of Float | 6.09% |
| Short Ratio (days to cover) | 0.3 |
Valuation Ratios
The PE ratio is -55311.38 and the forward PE ratio is -0.03.
| PE Ratio | -55311.38 |
| Forward PE | -0.03 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | -239280.53 |
| P/FCF Ratio | -51648.55 |
| PEG Ratio | n/a |
Enterprise Valuation
Allarity Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.14, with a Debt / Equity ratio of -0.47.
| Current Ratio | 0.14 |
| Quick Ratio | 0.14 |
| Debt / Equity | -0.47 |
| Total Debt / Capitalization | -89.59 |
| Cash Flow / Debt | -9.8 |
| Interest Coverage | -36 |
Financial Efficiency
Return on equity (ROE) is 4.33% and return on capital (ROIC) is 1165.42%.
| Return on Equity (ROE) | 4.33% |
| Return on Assets (ROA) | -1% |
| Return on Capital (ROIC) | 1165.42% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.38M |
| Employee Count | 5 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -717.00K |
| Effective Tax Rate | 0.06 |
Stock Price Statistics
The stock price has increased by -99.68% in the last 52 weeks. The beta is 0.29, so Allarity Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.29 |
| 52-Week Price Change | -99.68% |
| 50-Day Moving Average | 1.36 |
| 200-Day Moving Average | 36.07 |
| Relative Strength Index (RSI) | 30.9 |
| Average Volume (20 Days) | 606.78K |
Income Statement
In the last 12 months, Allarity Therapeutics had revenue of $0 and earned -$11.90M in profits. Earnings per share was $-0.01.
| Revenue | 0 |
| Gross Profit | -37.00K |
| Operating Income | -17.93M |
| Net Income | -11.90M |
| EBITDA | -12.08M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
The company has $166.00K in cash and $1.30M in debt, giving a net cash position of -$1.13M.
| Cash & Cash Equivalents | 166.00K |
| Total Debt | 1.30M |
| Net Cash | -1.13M |
| Retained Earnings | -94.45M |
| Total Assets | 20.38M |
| Working Capital | 12.95M |
Cash Flow
In the last 12 months, operating cash flow was -$12.74M and capital expenditures $0, giving a free cash flow of -$12.74M.
| Operating Cash Flow | -12.74M |
| Capital Expenditures | 0 |
| Free Cash Flow | -12.74M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ALLR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -0.98% |
| FCF Yield | -280.45% |
Analyst Forecast
Currently there are no analyst rating for ALLR.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Sep 11, 2024. It was a backward split with a ratio of 1:30.
| Last Split Date | Sep 11, 2024 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | -9.55 |
| Piotroski F-Score | 4 |